Reducing dietary levels of methionine can slow the onset and progression of inflammatory and autoimmune diseases


Significantly reducing dietary levels of the amino acid methionine could slow onset and progression of inflammatory and autoimmune disorders such as multiple sclerosis in high-risk individuals, according to findings published today in Cell Metabolism.

While many cell types in the body produce methionine, the immune cells responsible for responding to threats like pathogens do not.

Instead, the methionine that fuels these specialized cells, called T cells, must be ingested through food consumption.

Although methionine is found in most foods, animal products such as meat and eggs contain particularly high levels.

“Methionine is critical for a healthy immune system. Our results suggest, for people predisposed to inflammatory and autoimmune disorders like multiple sclerosis, reducing methionine intake can actually dampen the immune cells that cause disease, leading to better outcomes” said Russell Jones, Ph.D., the study’s senior author and program leader of Van Andel Institute’s Metabolic and Nutritional Programming group.

“These findings provide further basis for dietary interventions as future treatments for these disorders.”

Autoimmune disorders occur when the immune system mistakenly attacks and destroys healthy tissue.

For example, in multiple sclerosis — the most common inflammatory disease of the central nervous system — the myelin sheath that protects nerve cells in the brain and spinal cord is targeted by the immune system.

The subsequent damage impedes messages traveling to and from the brain, resulting in progressively worsening symptoms like numbness, muscle weakness, coordination and balance problems, and cognitive decline.

There currently are no treatments that significantly slow or stop multiple sclerosis without greatly increasing the risk of infection or cancer.

“What causes multiple sclerosis is still not completely understood. We know that genes related to the immune system are implicated but environmental factors also have a role to play,” said Catherine Larochelle, M.D., Ph.D., study co-author, and a clinician-scientist in neuroimmunology and neurologist at the Multiple Sclerosis Clinic at the Centre Hospitalier de l’Université de Montréal.

“The fact that metabolic factors like obesity increase the risk of developing multiple sclerosis makes the idea of dietary intervention to calm down the immune system particularly appealing.”

During an immune response, T cells flood the affected area to help the body fend off pathogens. Jones, Larochelle and their teams found dietary methionine fuels this process by helping “reprogram” T cells to respond to the threat by more quickly replicating and differentiating into specialized subtypes.

Some of these reprogrammed T cells cause inflammation, which is a normal part of an immune response but can cause damage if it lingers, such as the nerve damage that occurs in multiple sclerosis.

Although methionine is found in most foods, animal products such as meat and eggs contain particularly high levels.

The researchers also found that significantly reducing methionine in the diets of mouse models of multiple sclerosis altered the reprogramming of T cells, limiting their ability to cause inflammation in the brain and spinal cord.

The result was a delay in the disease’s onset and slowed progression.

“By restricting methionine in the diet, you’re essentially removing the fuel for this over-active inflammatory response without compromising the rest of the immune system,” Jones said.

He cautions that the findings must be verified in humans before dietary guidelines can be developed. The team also plans to investigate whether new medications can be designed that target methionine metabolism.

The study is the latest to spotlight methionine-restricted diets as possible treatments for disease. A 2019 study from the Locasale Lab at Duke University demonstrated that reducing methionine could improve the effects of chemotherapy and radiation in fighting cancer.

Other authors include Dominic G. Roy, Ph.D., Jocelyn Chen, M.Sc., Eric H. Ma, Ph.D., Radia M. Johnson, Ph.D., and Bozena Samborska, M.Sc., of the Goodman Cancer Research Centre, McGill University; Victoria Mamane, Rutger Koning, M.Sc., Audrey Daigneault, M.Sc., and Marie-Claude Bourgeois-Daigneault, Ph.D., of the Centre de Recherche du Centre Hospitalier de l’Université de Montréal; Brejnev M. Muhire, Ph.D., Ryan D. Sheldon, Ph.D., Kelsey S. Williams, Ph.D., J. Andrew Pospisilik, Ph.D., and Connie M. Krawczyk, Ph.D., of the Metabolic and Nutritional Programming group at Van Andel Institute; Sebastian Hayes, Ph.D., Mya Steadman, Victor Chubukov, Ph.D., and Thomas Roddy, Ph.D., of Agios Pharmaceuticals; Ekaterina Esaulova, Amanda Swain, Ph.D., and Maxim N. Artyomov, Ph.D., of Washington University at St. Louis; and Tatiana Shorstova, William Foulkes, MBBS, Ph.D., and Michael Witcher, Ph.D., of the Lady Davis Institute of the Jewish General Hospital of McGill University. Ma also is affiliated with VAI. Technical assistance was provided by Van Andel Institute’s Metabolomics Core, Flow Cytometry Core, and Bioinformatics and Biostatistics Core; the McGill-GCRC Metabolomics Core and Flow Cytometry Core; and the CRCHUM Flow Cytometry Platform.

Funding: Research reported in this publication was supported by the Multiple Sclerosis Society of Canada (Larochelle) and the Canadian Institutes of Health Research under award nos. MOP-399061 (Witcher) and MOP-142259 (Jones). The content is solely the responsibility of the authors and does not necessarily represent the official views of any funding organization.

Nutrition exerts profound effects on health and dietary interventions are commonly used to treat diseases of metabolic etiology.

Although cancer has a substantial metabolic component, the principles that define whether nutrition may be used to influence tumour outcome are unclear. Nevertheless, it is established that targeting metabolic pathways with pharmacological agents or radiation can sometimes lead to controlled therapeutic outcomes.

In contrast, whether specific dietary interventions could influence the metabolic pathways that are targeted in standard cancer therapies is not known. We now show that dietary restriction of methionine (MR), an essential amino acid, and the reduction of which has aging and obesogenic properties, influences cancer outcome through controlled and reproducible changes to one carbon metabolism.

This pathway metabolizes methionine and further is the target of a host of cancer interventions involving chemotherapy and radiation.

MR produced therapeutic responses in chemoresistant RAS-driven colorectal cancer patient derived xenografts and autochthonous KRASG12D+/−;TP53−/− -driven soft tissue sarcomas resistant to radiation.

Metabolomics revealed the therapeutic mechanisms to occur through tumor cell autonomous effects on the flux through one carbon metabolism that impacted redox and nucleotide metabolism, thus interacting with the antimetabolite or radiation intervention.

Finally, in a controlled and tolerated feeding study in humans, MR resulted in similar effects on systemic metabolism as obtained in responsive mice.

These findings provide evidence that a targeted dietary manipulation can affect specific tumor cell metabolism to mediate broad aspects of cancer outcome.

Van Andel Research Institute


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.